Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Elevance Health ( (ELV) ) is now available.
Elevance Health, Inc. announced that its officers will engage with investors to reaffirm the company’s earnings guidance for the full year 2025, projecting approximately $24.10 per diluted share, including net unfavorable items, and $30.00 per diluted share when adjusted. The company also maintains its guidance for a benefit expense ratio of about 90.0% for 2025, reflecting its current market and operational assessments. These projections highlight Elevance Health’s strategic positioning and operational expectations, although actual results may vary due to changing business factors.
The most recent analyst rating on (ELV) stock is a Buy with a $355.00 price target. To see the full list of analyst forecasts on Elevance Health stock, see the ELV Stock Forecast page.
Spark’s Take on ELV Stock
According to Spark, TipRanks’ AI Analyst, ELV is a Outperform.
Elevance Health’s overall stock score reflects strong financial fundamentals and attractive valuation, tempered by technical indicators suggesting limited short-term upside and challenges highlighted in the earnings call. The strategic board appointment adds a positive outlook for future governance and growth.
To see Spark’s full report on ELV stock, click here.
More about Elevance Health
Elevance Health, Inc. operates in the healthcare industry, providing a range of health insurance products and services. The company focuses on delivering diversified healthcare solutions, including insurance and pharmacy services, to meet the needs of its stakeholders.
Average Trading Volume: 2,377,734
Technical Sentiment Signal: Sell
Current Market Cap: $72.58B
Find detailed analytics on ELV stock on TipRanks’ Stock Analysis page.